Literature DB >> 20860313

Clinical manifestation of central nervous system tumor.

Soha A Alomar1.   

Abstract

Tumors of the brain and spinal cord (central nervous system, CNS) are rare when compared with other sites and other diseases that can affect the length of an individual's life. However, about 20,000 new cases of primary CNS tumors are diagnosed in the United States each year, not an insignificant number. The CNS is "locked" inside a rigid and nonexpandable calvarium (except in newborns and young children); therefore, any new growths (primary or secondary) can only grow at the expense of the structures already inside the skull or spinal column. The symptoms and signs or clinical manifestations of CNS tumors depend on the location and the growth rate of these tumors. Symptoms include general nonlocalizing and focal symptoms and signs. General signs, which reflect the increase in intracranial pressure, include drowsiness, confusion, headache, nausea, vomiting, sixth nerve palsy, papilledema, generalized seizures, and cognitive impairment. Focal signs and symptoms reflect the effect of the tumor on specific structures. Special imaging techniques (such as computed tomography, magnetic resonance imaging, and positron emission tomography) are essential for the localization of the lesion and for image-guided brain biopsies. The handling of these tiny biopsies often presents significant diagnostic challenges, especially at the time of frozen section examination.

Entities:  

Mesh:

Year:  2010        PMID: 20860313     DOI: 10.1053/j.semdp.2010.06.001

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  7 in total

1.  A randomized trial of cognitive rehabilitation in cancer survivors.

Authors:  M M Cherrier; K Anderson; D David; C S Higano; H Gray; A Church; S L Willis
Journal:  Life Sci       Date:  2013-09-05       Impact factor: 5.037

2.  White matter integrity assessed by diffusion tensor tractography in a patient with a large tumor mass but minimal clinical and neuropsychological deficits.

Authors:  Marco Bozzali; Sarah E MacPherson; Mara Cercignani; William R Crum; Tim Shallice; Jeremy H Rees
Journal:  Funct Neurol       Date:  2012 Oct-Dec

3.  Malignant gliomas: early diagnosis and clinical aspects.

Authors:  A Silvani; P Gaviani; E Lamperti; A Botturi; D Ferrari; G Simonetti; A Salmaggi
Journal:  Neurol Sci       Date:  2011-11       Impact factor: 3.307

4.  Expression of alarin in ependymoma and choroid plexus tumors.

Authors:  Nicole Eberhard; Serge Weis; Herbert Reitsamer; Barbara Kofler
Journal:  J Neurooncol       Date:  2013-06-13       Impact factor: 4.130

5.  Meningothelial cells react to elevated pressure and oxidative stress.

Authors:  Xiaorong Xin; Bin Fan; Josef Flammer; Neil R Miller; Gregor P Jaggi; Hanspeter E Killer; Peter Meyer; Albert Neutzner
Journal:  PLoS One       Date:  2011-05-17       Impact factor: 3.240

6.  Identification of the Gene Expression Rules That Define the Subtypes in Glioma.

Authors:  Yu-Dong Cai; Shiqi Zhang; Yu-Hang Zhang; Xiaoyong Pan; KaiYan Feng; Lei Chen; Tao Huang; Xiangyin Kong
Journal:  J Clin Med       Date:  2018-10-13       Impact factor: 4.241

7.  Lomustine analogous drug structures for intervention of brain and spinal cord tumors: the benefit of in silico substructure search and analysis.

Authors:  Ronald Bartzatt
Journal:  Chemother Res Pract       Date:  2013-04-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.